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Abstract
Background: Carrion’s disease affects small Andean communities in Peru, Colombia and Ecuador and is characterized by
two distinct disease manifestations: an abrupt acute bacteraemic illness (Oroya fever) and an indolent cutaneous eruptive
condition (verruga Peruana). Case fatality rates of untreated acute disease can exceed 80% during outbreaks. Despite being
an ancient disease that has affected populations since pre-Inca times, research in this area has been limited and diagnostic
and treatment guidelines are based on very low evidence reports. The apparently limited geographical distribution and
ecology of Bartonella bacilliformis may present an opportunity for disease elimination if a clear understanding of the
epidemiology and optimal case and outbreak management can be gained.
Methods: All available databases were searched for English and Spanish language articles on Carrion’s disease. In addition,
experts in the field were consulted for recent un-published work and conference papers. The highest level evidence studies
in the fields of diagnostics, treatment, vector control and epidemiology were critically reviewed and allocated a level of
evidence, using the Oxford Centre for Evidence-Based Medicine (CEBM) guidelines.
Results: A total of 44 studies were considered to be of sufficient quality to be included in the analysis. The majority of these
were level 4 or 5 (low quality) evidence and based on small sample sizes. Few studies had been carried out in endemic areas.
Conclusions: Current approaches to the diagnosis and management of Carrion’s disease are based on small retrospective or
observational studies and expert opinion. Few studies take a public health perspective or examine vector control and
prevention. High quality studies performed in endemic areas are required to define optimal diagnostic and treatment strategies.
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Introduction
Bartonella bacilliformis is a gram negative, facultative intracellular,
aerobic coccobacillus which is a member of the alpha-proteobac-
teria group along with Rickettsia and Brucella [1]. It is responsible for
a spectrum of disease which, despite its limited distribution, has
been given a multitude of names including bartonellosis, Carrion’s
disease, Oroya fever and verruga peruana.
The organism causes two distinct clinical syndromes. The initial
acute phase is characterised by fever and haemolytic anaemia and
has a reported mortality of 44% to 88% in untreated individuals [2].
The subsequent phase, which may occur weeks to months after the
acute illness (and there may or may not be a history of antecedent
illness), is characterised by the eruption of crops of miliary (figure 1),
mular (figures 2 and 3) or nodular skin lesions, or verrugas (‘‘warts’’),
containing sero-sanguinous fluid which exudes on contact.
Complications are not uncommon in the acute form and include
super-infections, most commonly with Salmonella species but also
with Toxoplasma, Histoplasma and others [3,4]. Haematological,
gastrointestinal [5], cardiovascular [6] and neurological [7]
complications also occur and in pregnancy, infection can lead to
miscarriage, premature labour and maternal death. Young children
are the most affected in endemic communities, partly because of a
predominantly younger population but also due to the presumed
protective immunity that develops with repeated infection [8].
The disease is restricted to the Andean cordillera in Peru
(figure 4), Ecuador, and Colombia with unconfirmed reports of
cases in Thailand in the 1960s [9] and sporadic cases in Bolivia,
Chile and possibly Guatemala [10]. Classically, endemic areas are
said to be confined to inter-Andean valleys positioned at right-
angles to the prevailing wind [9] and at altitudes between 500 to
3200 m above sea level [11]. This focality is mainly due to the
characteristics of its putative principal vector, Lutzomyia verrucarum
which has a weak, hopping flight and is intolerant of extreme
temperatures [9]. The vector has a crepuscular, endophilic feeding
habit and households are heterogeneously affected, with 18% of
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households accounting for 70% of cases in one series [12]. It is
thought that El Nin˜o events, which cause a warming in sea
temperature every 5–7 years, favourably affect vectors due to a
change in climatic conditions [13].
The history of the disease retains a degree of mystery as it has
not been fully established when the illness was first recognised.
Paleodiagnosticians still debate whether it was Carrion’s disease
that was responsible for a devastating epidemic in Huayna Capac’s
Incan empire which killed 200,000 of his people shortly before the
Spanish invasion and there remains debate about whether it was
this disease which killed almost half of Pizarro’s men in Coaque
during the Spanish colonization of Ecuador in 1532 [9].
The eponym Carrion’s disease recognises the contribution of
Daniel Alcides Carrion, a Peruvian medical student who in 1885
asked a fellow student to inoculate him with blood from a warty
cutaneous lesion from a diseased patient, in order to test his
hypothesis that the two clinical entities, which were considered at
the time to be different illnesses, were actually manifestations of
the same disease. His hypothesis was proven to be tragically
correct as he developed, and soon after succumbed to, the acute
febrile form of the illness hitherto known as Carrion’s disease,
becoming a martyr of Peruvian medicine [14].
This rich history is evident when visiting endemic areas as a
number of Quechua words exist for describing the disease and
traditional healers, or curanderos, have developed a range of
remedies for treating the disease.
Due to its focal geographical nature and the fact that it affects
small, isolated, rural communities, Carrion’s disease has been truly
neglected. Diagnostic and treatment guidelines [15,16] are
supported only by very low evidence studies and expert opinion.
However there are early suggestions of an expanding ecological
niche and the window of opportunity for disease elimination may
be starting to close; if definitive evidence-driven control efforts are
to succeed it will be important to quickly identify and address
important knowledge gaps.
Materials and Methods
Search methods
The following databases were used to search for articles in both
English and Spanish language from June to August 2010.
EMBASE, Global Health on OVID, HISA, LEYES, LILACS,
MEDLINE on OVID, PubMed, REPIDISCA, BASE and
ADOLEC.
References of key papers were examined for supplementary
studies. In addition, local experts in the field were contacted to
supply any further abstracts, unpublished data and conference
proceedings.
Only articles in English and Spanish were included in the
systematic review. No limits were placed on year of publication.
The following search terms were used:
Bartonel?osis
Bartonella AND bacilliformis
Verruga AND peru??ana
Carrion* AND disease
Oroya AND Fever
The articles obtained were transferred to EndNote reference
manager and checked for duplicates. The final Bartonella
bacilliformis library contained 480 articles. This list was further
scrutinized to select those of interest for the systematic review.
Further details on the search and selection method are provided
in Figure 5.
Inclusion criteria
The preliminary search was carried out to compile a
comprehensive Bartonella bacilliformis library. Due to the fact that
high-level evidence on the subject is limited, all types of trials and
articles were considered for inclusion.
The Endnote library was consulted for trials looking at
diagnosis, management, prevention, epidemiology and control of
B. bacilliformis. This search obtained 26 articles relating to
diagnosis, 26 on management, 41 on vectors and control and 31
about epidemiology and prevention.
Articles that were purely descriptive without any analysis, were
excluded from the review. In vitro studies looking at antibiotic
effectiveness were excluded unless this was the only data available
regarding that particular antibiotic. Diagnostic studies that did not
use a reference standard were also excluded. Some historical
articles could not be sourced. Articles that contained duplicated
data were excluded.
A total of 47 studies were considered to be of sufficient quality to
be included in the review; 11 on diagnosis, 15 on management, 9
on vectors and control and 12 on epidemiology and control. A
flow diagram of the selection process compiled using PRISMA
(Preferred Reporting Items for Systematic Reviews and Meta-
Analyses) guidelines can be seen as part of the supporting
documents (Figure S1).
All articles were rated according to level of evidence using the
Oxford Centre for Evidence-based Medicine’s Levels of Evidence,
March 2009 [17]. Please see Figure S3 for details. The full
EndNote library is freely available upon request.
Results
The principal characteristics and salient outcomes of the studies
are summarized in tables 1, 2, 3, and 4 according to subject.
Diagnosis (table 1)
Evaluations of diagnostics generally provide low quality
evidence and are plagued by ill-defined reference standards,
inappropriate control groups, frequent failure to disaggregate
diagnostic performance in acute and chronic forms of disease and
lack of application of currently accepted STARD guidelines [18].
Indirect fluorescence antibody test (IFA). Two studies
examined the diagnostic efficacy of IFA. The first, by Chamberlin
Author Summary
Carrion’s disease is one of the truly neglected tropical
diseases. It affects children predominantly in small Andean
communities in Peru, Colombia and Ecuador. Case fatality
rates of untreated acute disease can exceed 80% during
outbreaks. Diagnostic and treatment guidelines are based
on very low evidence reports and public health and
prevention programs have been limited. This paper
presents the first systematic review of Carrion’s disease in
Peru and encompasses a detailed analysis of all the highest
level evidence regarding not only diagnosis and manage-
ment but also vector control and prevention. In the review,
the authors highlight the considerable knowledge gaps in
this field and suggest a strategy for a renewed effort in its
investigation. The authors hope that through this work we
will be able to develop a better understanding of the
epidemiology, natural history and optimal approaches to
case and outbreak management. Ultimately, given the
apparently limited geographical distribution of this disease,
such an effort may present an opportunity for improved
science to lead to disease elimination.
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et al [19], tested 33 cases (blood culture or smear positive) and 101
controls and found a sensitivity of 85% and a specificity of 92%.
Four patients infected with other pathogens were tested for cross-
reactivity (two with syphilis, two with cat-scratch disease, caused
by Bartonella henselae) and one of each tested positive.
The second, by Knobloch et al [20], looked at 187 sera obtained
from patients resident in an endemic area of the Northern district
of Cajamarca and showed a much lower sensitivity of 45% when
compared to ELISA as a reference standard.
PCR. The only study found looking at PCR which used a
reference standard was by Padilla et al. [21] All 10 smear-positive
blood samples tested positive for B. bacilliformis and 5 additional
malaria positive samples were correctly identified as being negative
for Bartonella.
ELISA. The larger of two ELISA evaluation studies [22]
compared 27 lab-confirmed cases (by blood culture, smear or
PCR) to 40 healthy controls who were not from, and had never
visited endemic areas; and 10 sera of patients known to have
different infections. Sensitivity using IgM was superior to IgG
ELISA (85% vs 70%); specificity was 100% for both. One patient
with Salmonella infection tested positive but none of the other
pathogens cross-reacted with the test.
Eight of nine smear-positive patients tested by Maguin˜a [23]
between 1969 and 1992 had positive ELISA.
Sonicated immunoblot. Mallqui et al. [24] tested this
technique on 42 confirmed Carrion’s disease patients (blood
smear or biopsy positive). Two methods of antigen preparation
were tested; sonicated and glycine. For chronic disease the
sensitivity was 94% using both, whereas for acute cases, sensitivity
was 70% for sonicated and 30% for glycine. The specificity was
quoted as 100% for both when sera of healthy volunteers were
tested with immunoblot compared to blood smear. However,
when testing sera known to be positive for brucellosis, C. psittaci
and Coxiella burnettii, 34%, 5%, and 29% of the sera respectively
cross-reacted and gave a false positive result.
Thin blood smear. Despite being the oldest and most widely
employed method of diagnosis of B. bacilliformis, only two published
studies have looked at the sensitivity and specificity of this test. Ellis
et al. [25] found that out of 11 PCR positive acute cases tested
during the 1998 outbreak in the Urubamba region, only 4 were
Figure 1. Miliary lesion. Courtesy of C. Maguin˜a.
doi:10.1371/journal.pntd.0001819.g001
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thin smear positive, giving a sensitivity of 36%, and a positive
predictive value of 44%. A specificity of 96% was obtained as 125
individuals were thin smear negative out of 130 PCR negative
individuals.
Pachas et al. [26] found that of 352 confirmed acute and
chronic cases in Caraz (Ancash, Peru), 24% were thin smear
positive.
Western blot. Two studies by Maguin˜a et al. have looked at
Western blot compared to reference standard. One [27] used a
‘clinical expert’ to make a clinical diagnosis in 11 chronic patients and
the other [23] tested 9 culture-positive patients with acute disease. All
of these tested positive for B. bacilliformis with Western blot.
Management – acute disease (table 2)
There are no published controlled clinical trials of therapy for
acute or chronic Carrion’s Disease and interpretation of observa-
tional data is often complicated by lack of a standardized case
definition, lack of an adequate comparator arm, weak outcome
definitions and outcome ascertainment.
Ciprofloxacin. Studies of quinolone therapy have reached
divergent conclusions.
Minnick [28] and Sobraques et al. [29] in separate studies
published in 2008, found ciprofloxacin to have a minimum
inhibitory concentration (MIC) of 0.25 but disagreed on whether
this was high or low, with Sobraques [29] concluding that the
organism was highly susceptible to ciprofloxacin and Minnick [28]
discouraging its use, a suggestion purportedly later substantiated
by the description of constitutive mutations in the quinolone-
resistance-determining region of gyrase (gyrA) by Minnick [28]
and Angelakis [30].
Biswas [31] and del Valle [32] found that B. bacilliformis can
quickly become resistant to ciprofloxacin in vitro and therefore
concluded that its use should be discouraged in the treatment of
Carrion’s Disease, whilst Rolain [33] concluded that there was
‘moderate evidence for the use of ciprofloxacin from opinions of
respected authorities.’ This was based on unpublished reports.
Chloramphenicol. Three in vivo studies have been carried
out looking at the effectiveness of chloramphenicol, the first of
which was carried out by Urteaga [34] in the 1950s and involved
19 cases. Although the results reported that the majority, 79% (15),
made a rapid recovery, the study lacked details of sampling
methods and doses used.
Chloramphenicol was the most used antibiotic in the acute
phase in a cohort of 518 patients studied by Arroyo in Caraz [35].
The treatment resulted in clinical cure in 89%. However, none of
the patients received the recommended loading dose of 50 mg/kg
and 66.1% required a higher maintenance dose of 25 mg/kg and
indeed 39.1% required a prolonged treatment course greater than
14 days.
A similar study by Maguin˜a [23] carried out in Lima found that
95.4% of acute patients who had received chloramphenicol, either
alone or with another antibiotic, responded well though disaggre-
gated data for mono- and poly-microbial treatment was not
presented.
Rolain et al. [33] classify chloramphenicol as having good
evidence for use from one or more well-designed clinical trials,
though this is based on 2 observational studies [10,23] which
lacked in depth analysis.
Large blood transfusions. One historical case-series by
Hodgson [36] looked at the treatment of 2 acute cases with large
blood transfusions. The patients survived but took 32 and 45 days
to recover as well as 3.4 L and 8.15 L of blood respectively.
Management – chronic disease (table 2)
Rifampicin and streptomycin. Arroyo [35], in his study of
518 cases, found that rifampicin was the most popular treatment
Figure 2. Mular lesion. Courtesy of C. Maguin˜a.
doi:10.1371/journal.pntd.0001819.g002
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for chronic disease leading to clinical cure in 93.1% of patients,
though a large proportion (82%) required a prolonged treatment
course of greater than 21 days.
Rolain [33] reported rifampicin as having ‘good evidence for
use from one or more well-designed clinical trials’; this conclusion
is based on one observational study carried out by Maguin˜a et al.
[23] between 1969 and 1992 which found that 80% (37 of 46) of
patients treated with rifampicin had a good response compared
with 56% (5 of 9) who received streptomycin. From this data
Rolain et al. maintained that the strength of evidence for
streptomycin was the same as for rifampicin.
Rifampicin and azithromycin. In 2003, a group of
researchers from Caraz carried out a study [37] (as yet
unpublished) comparing azithromycin, the current 1st-line treat-
ment, to rifampicin in 127 cases. The definition of cure used was
reversion to negative blood cultures. Both antibiotics were equally
efficacious and achieved a similar ‘cure time’ of 3 to 4 weeks.
Sultamicillin and deflazacort. A single case report [38] was
published after the successful treatment of a 12-year old girl with
chronic verruga with 21 days of treatment (25 mg/kg of
sultamicillin, 0.7 mg/kg of deflazacort).
Vectors and control (table 3)
Though it is widely held that B. bacilliformis is transmitted by the
bite of an infected sandfly, evidence supporting this belief is
remarkably lacking.
Vector species. A number of studies have attempted to
implicate the Lutzomyia sandfly species in the transmission of
Carrion’s disease in different areas; most of them have involved
CDC light trap collections during outbreaks. However, since few
of them have identified B. Bacilliformis in the insect, the majority
only present circumstantial evidence that these sandfly species
could be the responsible vectors.
L. peruensis and, in smaller quantities, L. pescei were the only
species found in a study carried out during an outbreak in Cusco
[39]. Similar findings were reported by Ellis [25] who found only
L. peruensis during an outbreak in the Cuzco region. In this second
study, B. bacilliformis was identified using PCR in 2% of specimens
collected (n = 2).
A further study carried out by Caceres [40] found a great
abundance of Lu. robusta and Lu. maranonensis in intradomiciliary
areas in the provinces of Jaen, San Ignacio and Utcubamba,
however their possible role as vectors was not confirmed by PCR.
Figure 3. Mular lesion. Courtesy of C. Maguin˜a.
doi:10.1371/journal.pntd.0001819.g003
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A different species, L. serrana was found to make up 93.6% of
vectors collected in indoor CDC light traps and outdoor Shannon
traps during an outbreak in Huamalı´es, Hua´nuco in the high
jungle area of Peru. However, once again carriage of B. bacilliformis
by the sandflies could not be confirmed [41].
Vector characteristics. One study looking at vectorial
characteristics of L. verrucarum tried to ascertain whether vertical
transmission of B. bacilliformis occurred between adults and their
offspring [42]. The investigators were unable to make firm
conclusions regarding this, but they did find that the lifespan and
degree of oviposition in sandflies infected with low bacteraemic
blood(3%) was much longer and higher respectively compared
with those fed on high bacteraemic (80%) blood (p,0.001).
Control. Studies looking at the control of Lutzomyia are scarce
and none relate Lutzomyia control to Carrion’s disease incidence.
The first study was carried out in 1945 by Hertig and Fairchild
[43] in the Rimac Valley, about 40 miles from Lima, where L.
verrucarum and L. peruensis are abundant. Treatment of stone walls
with DDT produced a marked reduction of sandflies, not
quantified in the report, and treatment of stone walls combined
with house spraying reduced sandflies to an ‘extremely low level.’
The only other study found was a report of the control
programme in Caraz which took place between 2004 and 2008.
The initiative involved indoor house spraying with residual
insecticides [44]. The main conclusions drawn from this unpub-
lished report were that intra-domiciliary sandfly populations
remained remarkably low for over a year after spraying. This
was unexpected as these insecticides were marketed to have an
efficacy of 6 months. It is proposed that pyrethroids have
additional irritant and repellent effects on the vectors that last
longer than their known insecticide properties.
Epidemiology and prevention (table 4)
Incubation period. In 1947 Ricketts [45] studied a group of
patients who had recently visited endemic areas and proposed that
their incubation periods, as determined by culture positivity,
ranged from 20 to 100 days.
Immunisation. In 1943 Howe and his team [46] carried out
a case control study using military staff posted out to verruga zones
to test a crude vaccine made of 4 inactivated strains of B.
bacilliformis. Out of 22 vaccinated men, 55% had developed
positive blood cultures by the end of their duty period. This was in
Figure 4. Geographical distribution of bartonellosis in Peru. Courtesy of Ricardo Castillo (JHSPH).
doi:10.1371/journal.pntd.0001819.g004
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contrast to the control group, 90% (9 of 10) of which developed
positive cultures over a similar period of time.
Asymptomatic infection. In 1997, Chamberlin [12] and her
team in Caraz carried out a prospective cohort study which firstly
used PCR to detect the number of asymptomatic bacteraemics in
an endemic population; 0.5% of 555 were PCR positive. The
study population was also tested for past infection using IFA and
45% had positive antibodies. The investigators then followed an
abacteraemic cohort for 25 months monitoring them for clinical
features of Carrion’s disease. 127 cases were diagnosed in 25
months (12.7 per 100 person years) and cases were clustered, with
70% occurring in 18% of households.
Herrer, in the only other published epidemiological study done
in 1953 [47], measured serial culture positivity in a group of
students who had recently come to live in an endemic area. He
found that 29% (4 of 14) had asymptomatic infection but that 2
failed to produce positive cultures on repeated testing. He
concluded that this transient bacteraemia makes it less likely that
asymptomatic carriers are a reservoir for infection.
The effect of ‘El Nin˜o’. Two studies have looked specifically
at the effect of the ‘El Nin˜o’ phenomenon on the number of cases
of bartonellosis. One study [48] compared numbers of cases
between pre-, post- and 1997–1998 ‘El Nin˜o’ periods in the Cusco
and Ancash areas and found that sea surface temperature
correlated significantly with the number of cases of Carrion’s
disease.
The other study, by Chinga-Alayo et al. [13] described similar
findings during the 1983–1988 event in Ancash with an almost 4-
fold increase in monthly cases.
Reservoirs. Due to the sporadic nature of Carrion’s disease
outbreaks, various candidate reservoirs have been postulated in a
number of studies. Herrer [49], in 1953, proposed that euphorb
plants, which are found in great abundance in verruga zones and
yield a milky latex, may be a natural reservoir. However, in his
study he failed to recover B. bacilliformis from the plants, infect
seedlings or grow the microorganism in the presence of latex
dilutions.
Birtles [50] investigated the possibility of intradomicilliary
animals being reservoirs by testing 50 animals from the homes
of 11 children who had recently had the illness. Bartonella-like
organisms were isolated from 4 out of 9 small non-domesticated
rodents trapped inside the houses but they were not confirmed to
be B. bacilliformis.
Cooper et al. carried out two case-control studies [51,52] in
Zamora Chinchipe province, Ecuador, using questionnaires to
determine whether there was an excess of dead or dying animals in
case households compared to controls. Case households reported
seeing significantly more dead or dying rodents [51] and chickens
[52] than controls.
Discussion
Diagnosis
The Standards for the Reporting of Diagnostic Accuracy
Studies (STARD) checklist [18] states that good quality diagnostic
studies must describe the study population, their recruitment
(inclusion and exclusion criteria) and sampling method. They must
also use a reference standard and describe the definition of and
rationale for the cut-offs of index tests and reference standards
used.
Although these standards were published after some of these
studies were conducted, it is useful to note that the majority of
diagnostic studies were observational studies that lacked many or
all of the currently accepted criteria. Sampling methods were not
explained in any of the studies, making it difficult to exclude
selection bias, and the derivation of cut-offs for tests were not
explicitly explained, also potentially introducing bias. In cases
where a reference standard was used, this test varied from study to
Figure 5. Flowchart of article selection criteria.
doi:10.1371/journal.pntd.0001819.g005
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study, making it very difficult to make meaningful comparisons
between reports.
Though a positive blood smear, blood culture or histopatho-
logical finding can be considered diagnostic of Carrion’s disease
the lack of any of these does not necessarily exclude the diagnosis.
All diagnostic studies are to a degree therefore hampered by the
lack of an agreed reference standard and an important initial step
in future research efforts should be the agreement of a consensus
case definition.
The studies that reported the highest specificity were one
looking at ELISA [22] and another at sonicated immunoblot [24].
ELISA had a sensitivity of 85% and a specificity of 100% for
detecting both acute and chronic cases. However, the sensitivity of
immunoblot for detecting acute cases was only 70% at best and
even though the specificity of test was quoted as 100% the test then
cross-reacted with a number of other antigens.
IFA proved to have a good sensitivity and specificity, and the
study by Chamberlin [19] was classified as 3b, however its use may
be more appropriate in detecting past infection, rather than acute
diagnosis, as according to Chamberlin’s study, 45% of the
population in endemic areas may have antibodies without
necessarily having symptoms. This is also the case with ELISA
and immunoblot where antibodies may remain positive for some
time.
The studies on PCR [21] and Western Blot [23,27] showed
100% detection of acute cases (but 0% of chronic cases in the case
of PCR) and 100% specificity, however their sample sizes were
very small and lacked the majority of the currently accepted
STARD criteria [18].
The other problem with studies looking at these newer high-
tech diagnostic techniques is that no information was provided on
the cost, implementability and sustainability in endemic regions
where facilities are limited and the budget finite.
Blood smears are the cheapest and quickest method of diagnosis
for Carrion’s disease and are provided free of charge in the Caraz
region. However, although their specificity is very high, their
sensitivity is very low.
A new diagnostic tool that could also be used for disease
surveillance would be a very valuable addition to the armamen-
tarium, though the evaluation of a tool would clearly require a
consensus reference case definition to enable performance
characteristics to be defined.
Management
The literature on the management of acute and chronic
Carrion’s disease consists mainly of in vitro studies or case series.
This implies that our current treatment guidelines are supported
by level 4 and 5 evidence. In addition, the majority of these studies
lack a definition of cure which is problematic in Carrion’s disease
as although patients may be clinically ‘cured,’ they may still have
organisms in the circulation and therefore potentially be contrib-
uting to the transmission of the disease. Instead, the majority of the
studies used the proportion of patients who made a ‘good
recovery’ to define whether an antibiotic was effective or not.
Not only is this an unsatisfactory way of determining treatment
effectiveness but also, authors did not define what they meant by
‘good recovery.’ These issues make it difficult to draw meaningful
conclusions from these studies.
Acute disease. Only studies looking at quinolones and
chloramphenicol were found in the literature search but none
comparing the two.
There has been much discussion recently about the use of
quinolones in the management of acute Carrion’s disease due to
the publication of a number of experimental studies suggesting
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constitutive expression of gyrA mutations which confer quinolone
resistance. However, in vivo studies looking at this class of
antimicrobials are lacking and therefore it is difficult to draw
meaningful conclusions from these findings.
Although these are in vitro studies, and therefore evidence level
5, some go on to claim that ciprofloxacin is inadequate [28,30,32]
and should be removed from the current guidelines. One of these
studies [32] goes on to give an example of an in vivo case of
ciprofloxacin failure who died, however this patient was extremely
sick on presentation and did not recover despite simultaneously
receiving ciprofloxacin and ceftriaxone iv [53]. There is also some
discrepancy between studies in acceptable MICs for antibiotics with
some claiming that 0.25 makes ciprofloxacin inadequate [30] and
others claiming that a MIC of 0.25 makes it highly effective [29].
The evidence behind the use of chloramphenicol is only slightly
more established, with two level 4 observational studies [34,35]
Table 2. Summary of the studies on management and their level of evidence.
Reference Treatment N
Study design
and location
Type of
disease Outcome
Level of
evidence
Minnick, 2003 [28]
Angelakis, 2008 [30]
Ciprofloxacin N/A In vitro N/A Constitutive mutations in B. Bacilliformis
causing resistance to cipro identified
5
Minnick, 2003 [28]
Sobraques, 1999 [29]
Ciprofloxacin N/A In vitro N/A MIC = 0.25 5
Biswas, 2007 [31]
Del Valle, 2010 [32]
Ciprofloxacin N/A In vitro N/A B. bacilliformis quickly becomes
resistant to cipro
5
Urteaga, 1955 [34] Chloramphenicol, IV 19 Case series, Lima Acute 79% made a ‘rapid recovery’ 4
Arroyo, 2004 [35] Chloramphenicol 215 Observational study, Caraz Acute 89% achieved clinical cure 4
Maguin˜a, 2001 [23] Chloramphenicol 65 Case series, Lima Acute 95.4% responded well 4
Rolain, 2004 [33] Chloramphenicol 52 Minireview Acute Good evidence for use from one
or more well-designed clinical trials
3a
Hodgson, 1947 [36] Large blood
transfusions
2 Case series, Lima Acute Both survived 4
Arroyo, 2004 [35] Rifampicin 260 Observational study, Caraz Chronic 93.1% achieved clinical cure 4
Maguin˜a, 2001 [23] Rifampicin 46 Case series, Lima Chronic 80% responded well 4
Rolain, 2004 [33] Rifampicin 46 Minireview Chronic Good evidence for use from one
or more well-designed clinical trials
3a
Rolain, 2004 [33] Streptomycin 9 Minireview Chronic Good evidence for use from one
or more well-designed clinical trials
3a
Gonzalez, 2003
unpublished [37]
Rifampicin vs.
azithromycin
127 Case-control, Caraz Chronic Time to negative cultures for both
was 3–4 weeks
5
Gutierrez, 1998 [38] Sultamicilline and
deflazacort
1 Case report Chronic Successfully treated 5
doi:10.1371/journal.pntd.0001819.t002
Table 3. Summary of the studies on vectors and control and their level of evidence.
Reference Species/Control method Outcomes Study Location Level of evidence
Montoya, 1998 [39] L. peruensis and L. pescei Found in large and small quantities respectively Cusco 4
Ellis, 1999 [25] L. peruensis B. bacilliformis detected in 2% (2 of 104)
of specimens by PCR
Urubamba/Cusco region 3b
Ponce, 2002 [42] L.. verrucarum Unable to conclude whether vertical
transmission occurs as sample too small
Caraz 3b
Ponce, 2002 [42] L. verrucarum There is a significant difference between
lifespan and degree of oviposition between
sandflies infected with low bacteraemic
and high bacteraemic blood. (p,0.001)
Caraz 3b
Caceres, 1997 [40] Lu. robusta and
Lu. maranonensis
Found in intra-domiciliary areas San Ignacio, Jaen and
Utcubamba
4
Tejada, 2003 [41] L. serrana 93.6% of sandflies collected Huanuco 4
Hertig, 1948 [43] DDT Treatment of stone walls and house
spraying reduced numbers of vectors
Rimac Valley 4
Solorzano, 2009
unpublished [44]
Pyrethroids Pyrethroids may have additional irritant
and repellent effects which last longer
than the insecticide
Choquechaca, Yuracoto,
Caraz, Cullashpampa
5
doi:10.1371/journal.pntd.0001819.t003
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claiming a 79% and 89% recovery rate respectively and a
minireview [33] indicating that there is good evidence for its use
based on two small observational studies.
Chronic disease. The unpublished results of the study
carried out by a team of Caraz researchers led by Jesus Gonzalez
[37] are very compelling as this is the first study to compare two
antibiotics and the only study to use microbiological cure as the
end-point. Its results, which show that a weekly 1 g azithromycin
dose is just as effective as daily rifampicin, has important
implications. Not only could the weekly dose improve adherence
but it would avoid the indiscriminant use of an anti-tuberculous
drug in an area where multi-drug resistant (MDR) TB is a
problem.
Rifampicin is now the most widely used antibiotic in the chronic
phase and most patients have been found to respond well; 80%
and 93.1% respectively in two studies one of which was a
minireview and therefore level 3a evidence [23,35].
Studies looking at less-conventional treatments; large blood
transfusions for acute disease [36], and sultamicillin and
deflazacort for verruga peruana [38], involved only two and one
patient respectively and therefore their use in practice cannot be
determined.
Vectors and control
Though species of Lutzomyia are believed to be the principal
vector this assumption belies a marked lack of evidence.
B. bacilliformis was isolated from L. peruensis in the Cusco area
[25]. However the incrimination of L. robusta and L. maranonensis as
vectors in Jaen, San Ignacio and Utcubamba cannot yet be
confirmed. Similarly, L. serrano may be responsible for transmitting
Carrion’s disease in the high jungle area of Peru [41].
L. verrucarum has long been the presumed vector in the highly
endemic areas of Caraz and its surroundings. Although experi-
ments carried out to date have not yet established whether trans-
ovarial transmission of B. bacilliformis occurs in this species, it seems
that highly bacteraemic blood is detrimental to the sandfly, though
the significance of this is yet to be determined [42].
The studies on control are of very low evidence categories but
show that both DDT and pyrethroids are effective in reducing
sandfly populations in endemic areas. The study in Caraz [44]
additionally provides possible hypotheses for their continued
efficacy past the insecticide lifespan. Research looking at these
potential additional properties has not yet been carried out but the
idea is compelling and could allow a more cost-effective control
strategy to be designed for use in endemic areas
Epidemiology and prevention
The epidemiological studies done to date have provided us with
crude figures for incubation period (20 to 100 days) [45],
experimented with primitive vaccines which showed some possible
protection [46], and determined that significantly more cases of
Carrion’s disease occur during ‘El Nin˜o’ periods [14,48].
However, one study above all has provided crucial epidemio-
logical figures for Carrion’s disease in the highly endemic area of
Caraz. The study by Chamberlin et al. [13] which had rigorous
methodology and therefore classified as level 1b evidence,
provided the first accurate figures for incidence and prevalence
of past infection, though the point prevalence of asymptomatic
Table 4. Summary of the studies on epidemiology and prevention and their level of evidence.
Reference Topic N Main Outcomes Study Location Level of evidence
Ricketts, 1947 [45] Incubation period 13 19–100 days Lima 4
Howe, 1942 [46] Prophylactic
immunisation
32 55% of vaccinated developed positive
cultures vs. 90% of unvaccinated
Ancash 3b
Chamberlin, 2002 [13] Asymptomatic
bacteraemia
555 Point prevalence in January 1997: 0.5% Huaylas province 1b
Chamberlin, 2002 [13] Prevalence of past
infection
555 45% of the population Huaylas province 1b
Chamberlin, 2002 [13] Incidence of infection 555 12.7 per 100 person years Huaylas province 1b
Herrer, 1953 [47] Asymptomatic
bacteraemia
14 Unable to culture B. bacilliformis with
regularity from asymptomatic cases
San Juan 4
Chinga-Alayo, 2004 [14] The El Nin˜o
phenomenon
N/A Significant difference in monthly
bartonellosis incidence between el Nin˜o
and non-el Nin˜o periods
Cusco and Ancash 3b
Huarcaya Castilla, 2004 [48] The El Nin˜o
phenomenon
N/A There was a 4-fold increase in monthly
cases in El Nin˜o periods
Ancash 3b
Cooper, 1997 [50] Rats as a reservoirs for
bartonellosis
48 Peri-domicilliary dead rodents were found
more in case than control houses (p,0.05)
Zamora Chinchipe
province, Ecuador
4
Cooper, 1996 [51] Chickens as a reservoirs 8 Sick or dead chickens were found in
increased frequency in case compared
to control households (p,0.05)
Zamora Chinchipe
province, Ecuador
4
Birtles, 1999 [49] Domestic and peri-
domestic animals as
reservoirs
50 None of the 41 domestic animals were
infected. 5 of 9 other animals had
Bartonella-like organisms in blood
Huayllacallan valley,
Ancash
4
Herrer, 1953 [48] Euphorb plants as
reservoirs
N/A Unable to recover B. bacilliformis from
the plants, infect seedlings or grow the
microorganism in the presence of latex
dilutions.
Ancash 5
doi:10.1371/journal.pntd.0001819.t004
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bacteraemia of 0.5% was lower than previously thought, casting
doubt on the theory that humans are the sole reservoir.
Studies looking at alternative reservoirs are mostly inconclusive,
with euphorb plants [48] and intra-domicilliary animals [49–51]
failing to contain B. bacilliformis in a number of experiments.
Cooper’s studies in Ecuador, which found that households with
cases reported more dead or dying rodents and chickens, are also
unreliable (evidence level 4) as none of the animals were tested for
B. bacilliformis and the questionnaire methodology is potentially
subject to bias including responder bias if questions were asked in a
leading way by the interviewers who were not blind to whether
households were case or control.
Implications for practice
This work has provided an insight into what is known about
Carrion’s disease by looking at the highest-level evidence, and has
highlighted the important knowledge gaps which need to be
addressed if control efforts are to have any chance of success.
Diagnostic methods remain unsatisfactory in this disease, with
those that are cheap and readily available having a low sensitivity
and those that have a potentially higher sensitivity being more
expensive and impractical in most health centres in endemic
regions. New tools are needed and future evaluations require
rigour and clear case and outcome definitions. Optimal case and
outbreak management remains entirely unclear at present though
azithromycin may emerge as an excellent option.
Implications for research
Most of the studies included in the systematic review are level 4
or 5, indicating that there is a lack of high-level evidence guiding
our current practice in Carrion’s disease.
Development of effective surveillance tools to inform under-
standing of the epidemiology of disease (both clinical and
subclinical), harmonized case and outcome definitions, readiness
for outbreak investigation including evaluation of (putative) vector
control strategies, contact investigations and environmental and
reservoir host studies will all be important. Evaluation of treatment
strategies for individuals, households and perhaps communities
might also be worth pursuing. Understanding of immunity and
strain diversity is vestigial and advances might yield important
insights into pathophysiology.
There may be an opportunity to eliminate this ancient disease
which has been the scourge of poor, rural, mountain communities
for centuries but the expanding ecology of the putative vector may
limit the time available to seize this opportunity. An intensive
multidisciplinary research effort could yield the tools and strategies
required for success and the demonstration of this approach could
serve as a blueprint for other geographically-bound infectious
diseases. Daniel Carrion would be turning in his mausoleum
beneath Dos de Mayo Hospital in Lima if he only knew how little
we have progressed since his first (and last) big advance.
Study limitations
It was not possible to access some historical journals and there
were a number of articles published in smaller journals that were
not able to be accessed due to time and financial constraints. This
has unavoidably excluded some articles from the systematic
review.
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